title: [Regulation of the genes expression of CD4+ T-lymphocytes differentiation transcription factors by galectin-3 in vitro].
abstract: Now a number of CD4+ T-lymphocytes, known as Th1, Th2, Treg and Th17, is currently identified and well- studied. The methods basing on the targeted regulation of differentiation process of the Th-lymphocytes that carry out the immune response polarization attract an attention of scientists dealing with a correction of immune-mediated. In the present study, endogenous beta-galactoside-binding protein of the lectin family, galectin-3, was investigated as a regulator of T-cell homeostasis. A galectin-3 is known to be actively produced by tumor cells in malignant transformation and able to influence the processes of signal transduction, cell-cell cooperation and the implementation of programmed death. As cell differentiation processes are directly connected with the regulation of gene expression, we investigated the effect of recombinant galectin-3 on expression of mRNA of transcription.factors, which guide the differentiation of CD4+ lymphocytes. The study was performed on peripheral blood mononuclear cells of healthy individuals. The gene expression levels were evaluated by a real-time PCR. In the experiments in vitro, it has been first found the recombinant galectin-3 (0.5 mg/mL) up-regulating the expression of transcription factors Gata-3 and Rorc mRNAs and down-regulating the mRNA expression of transcription factors T-bet and FoxP3. Up to a concentration of 1 mg/mL recombinant galectin-3 stimulates Th-cells by dose-dependent manner, whereas at higher concentrations stimulating effect weakens, and inhibiting action starts prevailing. Thus, one can suppose that galectin-3 through regulation of lymphocytes differentiation promote development of allergic, autoimmune and neoplastic diseases that allows us to consider the galectin-3 as a.potential target for therapy of these diseases.
authors.forename: O A
authors.initials: OA
authors.lastname: Vasil'eva
authors.forename: V D
authors.initials: VD
authors.lastname: Iakushina
authors.forename: N V
authors.initials: NV
authors.lastname: Riazantseva
authors.forename: V V
authors.initials: VV
authors.lastname: Novitskiĭ
authors.forename: L A
authors.initials: LA
authors.lastname: Tashireva
authors.forename: E G
authors.initials: EG
authors.lastname: Starikova
authors.forename: A P
authors.initials: AP
authors.lastname: Zima
authors.forename: T S
authors.initials: TS
authors.lastname: Prokhorenko
authors.forename: T Iu
authors.initials: TIu
authors.lastname: Krasnova
authors.forename: I S
authors.initials: IS
authors.lastname: Nebesnaia
mesh_terms: D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D002454:Cell Differentiation / Q000187:drug effects*; D005260:Female; D050990:GATA3 Transcription Factor / Q000096:biosynthesis; D037502:Galectin 3 / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D008297:Male; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000096:biosynthesis
chemical_list: D050990:GATA3 Transcription Factor; D037502:Galectin 3; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; C539900:RORC protein, human